NCT05658562进行中（未招募）1 期
A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 46
- 试验地点
- 45
- 主要终点
- Overall response rate (ORR) by independent central review
研究概览
简要总结
[Phase I part] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed.
[Phase II part] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were diagnosed pathologically with DLBCL, NOS, DLBCL transformed from indolent B-cell lymphoma, or high-grade B-cell lymphoma with DLBCL morphology and with MYC and BCL2 and/or BCL6 rearrangements, based on the 2017 WHO classification.
- •Patients with relapsed or refractory disease despite 2 or more prior systemic therapies.
- •Japanese patients aged ≥ 18 years at the time of informed consent. For Japanese subjects, it should be confirmed that the parents who are related by blood to the subject must be Japanese.
- •Patients who have a lesion that can be assessed for staging and evaluated for response according to the Lugano criteria (2014). A lesion that has received radiotherapy as the most recent treatment will be considered as a measurable lesion only when progression has been documented following completion of the radiotherapy.
- •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening.
排除标准
- •Patients with a pathological diagnosis of Burkitt's lymphoma.
- •Patients with bulky disease with the longest dimension of ≥ 10 cm.
- •Patients with a history or complication of post-transplant lymphoproliferative disorders.
- •Patients with lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease.
- •Patients complicated with other active malignancies or patients with a history of other malignancies within 3 years before informed consent. However, the following are exceptional:
- •Non-melanoma skin cancer
- •Non-metastatic prostate cancer
- •Cervical carcinoma in situ
- •Ductal carcinoma in situ or lobular carcinoma in situ
- •Patients with clinically significant third space fluid accumulation (e.g., ascites requiring drainage or pleural effusion requiring drainage or associated with shortness of breath).
- •Patients who underwent autologous hematopoietic stem cell transplantation (AHSCT) within 30 days prior to the start of study drug administration (Cycle 1 Day 1).
- •For the Phase I part, patients with prior allogeneic stem cell transplantation (Allo-HSCT) before the start of study drug administration (Cycle 1 Day 1). For the Phase II part, patients undergoing Allo-HSCT within 60 days prior to the start of study drug administration (Cycle 1 Day 1).
- •Patients who had a positive HIV antigen-antibody test or HIV antibody test.
- •Patients positive for HBs antigen, HBc antibody, or HBs antibody. However, patients who meet any of the following are eligible:
- •The patient's HBs antibody positivity is clearly due to vaccination.
- •Patients who are positive for HBs antibody and/or HBc antibody with HBV-DNA not detected and agree to undergo HBV-DNA tests once a month from the start of study drug administration to at least 12 months after the completion of study drug administration.
- •Patients positive for HCV antibody. However, patients with negative HCV-RNA are eligible.
- •Patients who received anticancer therapy during the following periods prior to the start of study drug administration (Cycle 1 Day 1).
- •Cytotoxic chemotherapy: within 14 days.
- •Antibody therapy: within 5 half-lives or 14 days, whichever is longer (including monoclonal antibody preparations, radioimmunoconjugates, or antibody-drug conjugates). Within 14 days for rituximab, anti-CD3/CD20 bispecific antibody.
- •Radiotherapy: within 14 days
- •CAR-T therapy: within 100 days
- •Other anticancer therapy: within 14 days
- •Patients who received treatment with any other investigational product within 14 days prior to the start of study drug administration (Cycle 1 Day 1). However, for the Phase I part, patients who received any other investigational product within 14 days or 5 half-lives, whichever is longer, before the start of study drug administration (Cycle 1 Day 1).
研究组 & 干预措施
MT-2111 dosing regimen
Experimental
干预措施: MT-2111 (Drug)
结局指标
主要结局
Overall response rate (ORR) by independent central review
时间窗: From the date of the first dose of treatment until the date of discontinuation or completion of the study (Up to 48 months)
次要结局
- Duration of response (DOR)(The time from the date of first observation of complete response (CR) or partial response (PR) until progressive disease (PD) or death in patients with CR or PR observed (Up to 48 months))
- Overall survival (OS)(The time from the date of first dose until death regardless of the occurrence of intercurrent event (Up to 48 months))
- Progression-free survival (PFS)(The time from the date of first dose until PD or death (Up to 48 months))
- Relapse-free survival (RFS)(The time from the date of first observation of CR until PD or death in patients with CR observed (Up to 48 months))
- Adverse events and adverse drug reactions(From the start of premedication until 15 weeks after the last dose of the study drug or until the start of new anticancer therapy, whichever comes first.)
- Eastern Cooperative Oncology Group (ECOG) Performance Status(Screening to end of treatment (up to 30 days after the last dose) or data cut off)
- Body weight(Screening to end of treatment (up to 30 days after the last dose) or data cut off)
- 12-lead electrocardiogram (heart rate)(Screening to end of treatment (up to 30 days after the last dose) or data cut off)
- 12-lead electrocardiogram [RR, PR, QRS, QT (QTcF)](Screening to end of treatment (up to 30 days after the last dose) or data cut off)
- 12-lead electrocardiogram (presence or absence of abnormal findings)(Screening to end of treatment (up to 30 days after the last dose) or data cut off)
- Complete response rate (CRR)(From the date of the first dose of treatment until the date of discontinuation or completion of the study (Up to 48 months))
- Serum drug concentration(Cycle 1 (each cycle is 3 weeks): Days 1, 2*, 5*, 8, and 15. Cycle 2: Days 1, 2*, 8, and 15. Cycle 3: Days 1 and 8*. Odd numbered Cycles: Day 1. End of treatment (up to 13 months after first dose), 15 weeks after the last dose. *Phase 1 only.)
- Anti-drug antibodies (including neutralizing antibodies)(Cycle 1 (each cycle is 3 weeks): Days 1 and 15. Cycle 2: Day 1. Odd numbered cycles: Day 1. End of Treatment (up to 13 months after first dose) and 15 weeks after the last dose.)
研究者
研究点 (45)
Loading locations...
相似试验
招募中
1 期
A Phase I/II Study of MT-2111 in Patients with Relapsed/Refractory DLBCPatients with relapsed/refractory DLBCJPRN-jRCT2021220031Kazuoki Kondou49
已完成
1 期
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersHer2 Amplified Solid TumorsMetastatic Breast CancerNCT00911898Merrimack Pharmaceuticals20
已完成
1 期
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid TumorsSolid TumorMetastatic CancerAdvanced CancerNCT04678921I-Mab Biopharma US Limited16
尚未招募
1 期
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid TumoursAdvanced Solid TumoursNCT05537051Biotheus Inc.30
已完成
1 期
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy SubjectsHealthy VolunteersNCT03905291Medy-Tox25